Demographer Lyman Stone works from 11% of people on GLP-1s lowering obesity by about 3 points, and projects what wider uptake could do.
Recap by typeshit. Post by Lyman Stone 石來民 🦬🦬🦬 on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A short wellness post arguing that the scale misses part of the picture for people on semaglutide or tirzepatide. Light on specifics.
Mounting research suggests GLP-1 medications used for diabetes and weight loss may also dampen people's desire for drugs and alcohol.
Loading…